Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Moderna (MRNA)
NASDAQ:MRNA
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-3.03Last Year’s EPS
-3.07Same Quarter Last Year
Based on 16 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 14, 2025
|% Change Since: 5.67%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Neutral
Moderna's earnings call reflected a challenging year with significant revenue declines and net losses. However, the company demonstrated strong cost-saving measures and maintained a substantial cash position. Progress in the product pipeline and operational efficiency goals offer potential for future growth.Company Guidance
During Moderna's Fourth Quarter 2024 Conference Call, the company provided detailed financial guidance and updates on their product pipeline. For the fiscal year 2024, Moderna reported revenue of $3.2 billion, achieving cost savings of $2.6 billion compared to 2023, but also posted a net loss of $3.6 billion. They concluded the year with $9.5 billion in cash and investments. The fourth quarter product sales were $0.9 billion, with $0.2 billion from the U.S. and $0.7 billion internationally. The company also discussed their focus on ten high-value programs expected to drive growth, including respiratory vaccines and oncology treatments. For 2025, they anticipate revenue between $1.5 billion and $2.5 billion, with continued cost management targeting $5.5 billion in cash costs. Moderna's strategic priorities include driving sales of approved products, focusing on late-stage pipeline approvals, and maintaining cost efficiency.Significant Cost Reductions
Moderna achieved $2.6 billion in cost savings in 2024, a 27% reduction from 2023, driven by manufacturing footprint resizing, pricing renegotiations, and improved operational efficiencies.
Substantial Cash Position
The company ended 2024 with $9.5 billion in cash and investments, up from $9 billion, due to efficient management of OpEx, CapEx, and working capital.
Progress in Product Pipeline
In 2024, Moderna became a multi-product company with the approval of mRESVIA and positive Phase 3 results in four respiratory vaccine programs. Three products were filed for FDA approval.
Operational Efficiency Goals
Moderna plans to reduce cash costs to $5.5 billion in 2025 and $5 billion in 2026, aiming for over $1 billion in cost reductions.
---
MRNA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MRNA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 14, 2025 | $31.92 | $32.99 | +3.35% |
| Nov 07, 2024 | $51.81 | $50.28 | -2.95% |
| Aug 01, 2024 | $119.22 | $94.17 | -21.01% |
| May 02, 2024 | $111.46 | $125.59 | +12.68% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Moderna (MRNA) report earnings?
Moderna (MRNA) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Moderna (MRNA) earnings time?
Moderna (MRNA) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MRNA EPS forecast?
MRNA EPS forecast for the fiscal quarter 2025 (Q1) is -3.03.
---
